EGFR targeted therapy for lung cancer: are we almost there?

In the era of precision medicine, predictive biomarkers have revolutionized the therapeutic approach to advanced non-small cell lung cancer (NSCLC) (1). So far, sensitizing epidermal growth factor (EGFR) mutations (exon 19 deletion or exon 21 L858R) and anaplastic lymphoma kinase (ALK) rearrangements are among the best described targetable alterations, against which highly effective small molecules tyrosine-kinase inhibitors (TKIs) have been developed.